Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13645924 | 0.89 | TRPV1 (0.35) | ACACBMTNR1AMTNR1BALDH1A1TRPV1 | |
| SCHEMBL15830066 | 0.85 | CHRM1 (0.31) | CHRM1 | |
| SCHEMBL13780653 | 0.83 | ACACB (0.37) | ACACBMTNR1AMTNR1BALDH1A1TRPV1 | |
| SCHEMBL13780656 | 0.82 | ALDH1A1 (0.38) | ALDH1A1CHRM1 | |
| SCHEMBL13780937 | 0.80 | ACACB (0.36) | ACACBMTNR1AMTNR1BALDH1A1TRPV1 | |
| SCHEMBL20014334 | 0.80 | CHRM1 (0.32) | CHRM1 | |
| SCHEMBL21513624 | 0.79 | ACACB (0.37) | ACACBMTNR1AMTNR1BALDH1A1CHRM1 | |
| SCHEMBL13780652 | 0.78 | CHRNB2 (0.33) | ALDH1A1 | |
| SCHEMBL13645919 | 0.78 | CTSK (0.40) | ACACBMTNR1AMTNR1B | |
| SCHEMBL12384299 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | ACACB 4200/4885MTNR1A 2091/4885MTNR1B 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.